Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Many of the credit card offers that appear on the website are from credit card companies from which ThePointsGuy.com receives compensation. This compensation may impact how and where products appear ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Bernstein reduced its price target to $1,000, retaining an Outperform rating, following lower-than-expected Dupixent sales and anticipated EPS shortfall. TD Cowen decreased its price target to $ ...

I review privacy tools like hardware security keys, password managers, private messaging apps and ad-blocking software. I also report on online scams and offer advice to families and individuals ...

Hybrid and Electric Car Reviews 2025 Volvo EX30 Review Feb 25, 2025 11 Min Read Expert Reviews 2025 Mitsubishi Outlander First Drive Review + Video Feb 24, 2025 8 Min Read Hybrid and Electric Car ...